ReviewJournal of hematology & oncology2017
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.
Review in Journal of hematology & oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 68 citations in OpenAlex.
- Integrative prognostic modeling of ovarian cancer: incorporating genetic, clinical, and immunological markers.Discover oncology · 2025Article
- A radiomics model fusing clinical features to predict microsatellite status preoperatively in colorectal cancer liver metastasis.BMC gastroenterology · 2023Article
- Emerging evidence and treatment paradigm of non-small cell lung cancer.Journal of hematology & oncology · 2023Review
- PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma.Frontiers in immunology · 2023Article
- A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma.Journal of translational medicine · 2022Article
- Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.Journal of hematology & oncology · 2022Review
- An immune-related nomogram model that predicts the overall survival of patients with lung adenocarcinoma.BMC pulmonary medicine · 2022Article
- Tumor stemness and immune infiltration synergistically predict response of radiotherapy or immunotherapy and relapse in lung adenocarcinoma.Cancer medicine · 2021Article
- Deciphering the Immune-Tumor Interplay During Early-Stage Lung Cancer DevelopmentFrontiers in oncology · 2021Review
- Induction of Therapeutic Protection in an HPV16-Associated Mouse Tumor Model Through Targeting the Human Papillomavirus-16 E5 Protein to Dendritic Cells.Frontiers in immunology · 2021Article
- Improving the Lung Cancer Clinical Trial Development by Incorporating Competing Risk Factors.BioMed research international · 2021Article
- Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China.Frontiers in oncology · 2021Review
- Accelerated elimination of human cancer cells by a CD40 agonist antibody combined with a PD-1 antagonist in CD4-depleted mice.Oncology letters · 2019Article
- Liquid biopsy for lung cancer immunotherapy.Oncology letters · 2019Review
- Emerging therapies for small cell lung cancer.Journal of hematology & oncology · 2019Review
- Emerging therapies for non-small cell lung cancer.Journal of hematology & oncology · 2019Review
- PEST-containing nuclear protein regulates cell proliferation, migration, and invasion in lung adenocarcinoma.Oncogenesis · 2019Article
- Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.The oncologist · 2019Review
- PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.The oncologist · 2019Review
- LncRNA TP73-AS1 promoted the progression of lung adenocarcinoma via PI3K/AKT pathway.Bioscience reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this immunotherapy in 270 clinical studies. However, Chinese clinical trials of these agents remain in the early stages. We summarize the ongoing international and domestic clinical trials using PD-1 and PD-L1 inhibitors to treat lung cancer. This information can help researchers better understand the active and approved clinical trials in China, as well as the ongoing research regarding PD-1 and PD-L1 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.